Latest News and Press Releases

GENEVA, Switzerland January 3, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today...

GENEVA, Switzerland December 20, 2021 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today...

GENEVA, Switzerland December 20, 2021 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today...

-European Commission Decision Anticipated in Q1 2022- -CHMP recommendation follows the recent acceptance of the linzagolix uterine fibroids NDA by the U.S. Food and Drug Administration-   Ad hoc...

-European Commission Decision Anticipated in Q1 2022- -CHMP recommendation follows the recent acceptance of the linzagolix uterine fibroids NDA by the U.S. Food and Drug Administration-   Ad hoc...

 Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – December 13, 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and...

  -Symposium on oral GnRH antagonists and personalized therapeutic approaches for women with uterine fibroids to be hosted Friday, December 10 at 1 p.m. CET- -52-Week Data from the Phase 3...

GENEVA, Switzerland December 2, 2021 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today...

FDA Accepts NDA for Linzagolix for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids   Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA,...

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange   GENEVA, Switzerland November 22, 2021 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and...